Esoteric Testing Industry To Observe Highest CAGR in Asia-Pacific

The esoteric testing market was USD 23,373 million in 2022, and it will grow at a CAGR of 11.70% during 2022–2030, to reach USD 56,643 million by 2030 as per a report by P&S Intelligence. This is because of the increasing incidence of genetic diseases, infectious, and chronic, as well as the rising elderly population.

To learn more about this report: https://bit.ly/3Hhd27U

Moreover, the rise of advanced technologies, for instance, gene sequencing and gene mass spectrometry, which allowed for diagnostic needs and confident diagnoses; and the growing number of tests are driving the industry. 

COVID-19 has increased the need for infection screening centers and RT-PCR tests for the detection of the virus. 

Chronic diseases, including cancer, diabetes, and heart disease, are rising all over the world. Likewise, the incidence of infectious diseases is increasing alarmingly, particularly malaria, dengue, tuberculosis, HIV, and hepatitis B & C. 

The highest CAGR is projected in the genetic testing category, because of the government support for accurate and fast diagnoses, the increasing number of genetic disorder patients, the advancing genetic testing technologies, and rising awareness of genetic testing for cancer and prenatal screening. 

CLIA held the largest share in the industry, and it will remain on top in the future. This is because of its high performance, in terms of accurate detection and effective diagnosis.

On the other hand, the DNA sequencing category will witness the fastest growth, due to the increasing incidence of dengue, AIDS, neurological disorders, cancer, and hepatitis. 

With approximately 36% share, North America was the largest industry in 2022, and it will grow at a significant rate in the future. This is credited to the large population of patients suffering from chronic ailments and the elderly, the existence of leading companies, and the high per capita income and healthcare expenditure.    

APAC will advance with the highest CAGR in the future. It is because of the rising awareness regarding esoteric testing, the increasing focus of companies on expanding their operations in South Korea, Australia, and India, and the mounting incidence of chronic illnesses. 

Due to gene sequencing and gene mass spectrometry, the industry will grow even more in the coming years.

Read More

Growing Molecular Quality Controls Market Customer Base at Accredited Clinical Laboratories

The total size of the molecular quality controls market was $191.2 million in 2022, which will reach $313.7 million by 2030, propelling at a rate of 6.4% in the years to come, as per a statement by P&S Intelligence.

Get the sample pages of this report: https://bit.ly/414r44y

The independent controls category had the largest share of about 40% in 2022. This is due to the fact that they are produced independently of calibrators, instruments, and reagents, and tests have the supreme sensitivity rate as a result of their tremendously precise, unbiased, and independent valuation of a testing system's or technique's performance.

The single-analyte controls category had a share of over 60%, in 2022, and it will maintain the same in the years to come. This is for the reason that hospitals often use singleplex assays; and with the use of single-analyte, they have benefits for example, easy investigation and understanding and decreased chance of cross-responsiveness, amongst others.

Multi-analyte will witness stable growth rate, about 7%, in the years to come. This can be owing to the progressions in tech and the expansion of new multi-analyte and multi-instrument controls. Clinical labs can save money by the use of these state-of-the-art devices, which integrate frequent instrument-specific controls into a single instrument. 

Additionally, by doing away with the necessity for separate quality control actions for each analyte, these controls are responsible for less time consumption. The diagnostic labs dominated the molecular quality controls market, about 35%, in 2022. 

This is due to the fact that the existence of numerous accredited labs in dissimilar regions, which concentrates in services with the use of molecular technology; QC procedures are employed more frequently; regulatory actions are happening more regularly; molecular diagnostics are becoming more expensive; and Alzheimer, diabetes, and cancer cases are increasing, leading to the opening up of numerous labs every year.

North America dominated the industry with about 45%, in 2022. This is because of the high incorporation of leading-edge infra, the enhanced quantity of diagnostic facilities, and the improved count of authorized clinical labs in the region. 

Furthermore, the cutting-edge medical facilities in Canada and the U.S., the existence of top manufacturers, and easy access to improved products and techs drive the regional market. In North America, the U.S. has a higher revenue due to large patient population.

Europe follows North America. This is chiefly credited to the snowballing cancer research and related biomarkers and the increasing cancer cases. A study has claimed that there will be a boom in cancer prevalence in Europe, because of the increasing elderly population, as they are prone to long-lasting ailments.

It is because of the increasing count of accredited clinical labs, the demand for molecular quality control will be on the rise in the years to come. 

Read More